Fineline Cube

Follow:
14482 Articles
CompanyDeals

Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer

Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China
CompanyDrug

Grand Pharma Wins NMPA Approval for GPN01768 – First Targeted Therapy for Demodex Blepharitis in China

CompanyDrug

GSK Wins FDA Approval for Lynavoy – First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close

Eli Lilly Submits Obesity Policy Recommendations at China Development Forum – Advocates for Weight Management in 15th Five‑Year Plan
Company

Eli Lilly Submits Obesity Policy Recommendations at China Development Forum – Advocates for Weight Management in 15th Five‑Year Plan

Xuanzhu Biopharma Completes Anaprazole Phase III Enrollment – 500‑Subject Reflux Esophagitis Trial Advances Novel PPI
CompanyDrug

Xuanzhu Biopharma Completes Anaprazole Phase III Enrollment – 500‑Subject Reflux Esophagitis Trial Advances Novel PPI

CompanyDrug

Hengrui Pharma’s SHR-3836 Wins NMPA Approval for Multiple Myeloma – First-in-Class Anti-Tumor Agent Enters Clinical Development

CompanyDrug

Hengrui Pharma’s HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer – Second Indication Expands Trastuzumab Rezetecan Franchise

CompanyDrug

Innovent Biologics Doses First Patient in Phase 3 Tigulixostat Study – Next‑Gen Xanthine Oxidase Inhibitor Targets Gout Market

Dizal Reports Positive WU‑KONG28 Results – ZEGFROVY First‑Line Win Positions as First Chemo‑Free EGFR exon20ins NSCLC Therapy
CompanyDrug

Dizal Reports Positive WU‑KONG28 Results – ZEGFROVY First‑Line Win Positions as First Chemo‑Free EGFR exon20ins NSCLC Therapy

CompanyDrug

CSPC Pharma’s SYH2082 Wins NMPA Approval – Long‑Acting GLP‑1/GIP Dual‑Biased Agonist Enters Obesity Clinical Trials

CompanyDrug

Haihe Biopharma Wins Japan Approval for Risovalisib – First PI3Kα Inhibitor for Ovarian Clear Cell Carcinoma

Policy / Regulatory

China NHC Issues Medical Technology Evaluation Procedures – New Framework Triggers Restrictions or Bans on Controversial Clinical Practices